Mondolino leaves Morgan Lewis for McDermott Will
Dennis Mondolino is joing McDermott Will.
Ray Lupo: "With this addition in New York we now have a formidable IP litigation presence in each of our eight U.S. offices, in addition to our European offices. Dennis and his group will be especially effective
in advancing our pharmaceutical focus as part of our expanding life sciences IP practice."
Mondolino argued for Glaxo SmithKline in the case Glaxo v. Apotex, in the Ceftin matter. One issue there was the meaning of amorphous, as used in a claim and as previously discussed in Glaxo v. Ranbaxy, 262 F.3d 1333 (CAFC 2001). The art upon which Apotex relied had been before the PTO and thus the burden was especially difficult. Al-site, 174 F.3d 1308. A bigger issue was that of attorneys fees, arising from the fact that Apotex did not receive an opinion of counsel. In the Glaxo did not receive attorneys fees.
(post 981)
Ray Lupo: "With this addition in New York we now have a formidable IP litigation presence in each of our eight U.S. offices, in addition to our European offices. Dennis and his group will be especially effective
in advancing our pharmaceutical focus as part of our expanding life sciences IP practice."
Mondolino argued for Glaxo SmithKline in the case Glaxo v. Apotex, in the Ceftin matter. One issue there was the meaning of amorphous, as used in a claim and as previously discussed in Glaxo v. Ranbaxy, 262 F.3d 1333 (CAFC 2001). The art upon which Apotex relied had been before the PTO and thus the burden was especially difficult. Al-site, 174 F.3d 1308. A bigger issue was that of attorneys fees, arising from the fact that Apotex did not receive an opinion of counsel. In the Glaxo did not receive attorneys fees.
(post 981)
posted by Lawrence B. Ebert at 8:48 AM
0 Comments:
Post a Comment
<< Home